In The News

After nine months of suffering, isolation and economic downturn on an unprecedented international scale, the expedited development and approval of COVID-19 vaccines has shown us the light at the…

Washington, DC – January 20, 2021 - Friends of Cancer Research (Friends) would like to applaud President Biden for selecting Dr. Janet Woodcock to serve as acting Commissioner of the U.S. Food and…

On a campaign stop in Iowa in June 2019, Joe Biden declared, “I promise you if I'm elected president, you're going to see the single most important thing that changes America: We're gonna cure cancer…

Key Prominent Players Covered in the COVID-19 Diagnostics Market Research Report Are PerkinElmer Inc., Quest Diagnostics Incorporated, Quidel Corporation, Siemens Healthcare GmbH, Abbott, Thermo…

Last month at COTA, we announced a three-year extension of our Research Collaboration Agreement with the FDA, with an immediate focus on using real-world data (RWD) to examine the pandemic’s impact…

Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy Within recent years, the field of oncology has seen major advancements in regards to therapeutic options for patients.…

Bipartisan MODERN Labeling Act Included Washington, DC – December 22, 2020 - Friends of Cancer Research (Friends) applauds the bipartisan work of the House and Senate to bolster the U.S. economy and…

Congress’ year-end coronavirus relief and spending deal appears to include FDA-related provisions that would extend the agency’s rare disease priority review voucher program until 2024, allow…

The Friends of Cancer Research (FOCR) held the first of a two-part virtual annual meeting, which focused on ways of updating expedited drug approvals at the FDA. Modernization of expedited approval…

Since its creation in 1992 the Accelerated Approval (AA) program at the U.S. Food and Drug Administration (FDA) has been a boon for patients receiving new oncology drugs. One assessment cited in a…